Saturday, October 31, 2026
ExploreSearch
Finance Via News

Capital Allocation

2 articles

$122 Billion OpenAI Round Signals Coming Infrastructure Spending Wave

$122 Billion OpenAI Round Signals Coming Infrastructure Spending Wave

OpenAI's $122 billion funding round is expected to trigger a capital reallocation into AI infrastructure within 6-12 months. Compute providers, data center operators, and networking firms are positioned to absorb the downstream spending. Market conditions favor the thesis: the S&P 500 is approaching record highs in a risk-on environment.

LM Salvado•
Duke Energy's $103B Capex Plan Shows AI Power Demand Is Rewriting Utility Budgets

Duke Energy's $103B Capex Plan Shows AI Power Demand Is Rewriting Utility Budgets

Duke Energy has committed to a $103B five-year capital expenditure program anchored by electricity supply agreements with major hyperscalers, with its CEO signaling the figure will increase. The plan includes next-generation nuclear power, reflecting hyperscaler demand for continuous baseload-grade electricity. AI infrastructure buildout has now grown large enough to structurally reshape utility capital allocation across the sector.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com